Analyst Research

Report Title Price
Thomson Reuters Stock Report - ALKERMES PLC (ALKS-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy
Market Edge Equity Research Report
Provider: Market Edge
$10.00
Buy
Alkermes Plc
Provider: S&P Capital IQ – STARS Reports
$104.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Alkermes plc Reaffirms FY 2013 Guidance-Conference Call


Thursday, 26 Jul 2012 12:30pm EDT 

Alkermes plc announced that it is on track to meet expectation of over $0.5 billion in revenue, and non-GAAP net income in the range of $85 million to $105 million for fiscal 2013. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $0.5 billion, net profit of $90 million for fiscal 2013. 

Latest Developments for Alkermes Plc

Latest Key Developments in Biotechnology

Company Quote

Alkermes Plc
(ALKS.O)
31.98
0.94 +3.03%
21 May 2013